EUROPE DNA VACCINES MARKET 2019-2027

Lifesciences | Pharmaceuticals

EUROPE DNA VACCINES MARKET 2019-2027

Market By Type, Application, Technology And Geography | Forecast 2019-2027

Request Free Sample

Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

A study by Triton Market Research depicts that the Europe DNA vaccines market is expected to grow at a CAGR of 41.47% in terms of revenue for the forecasted years 2019-2027.

The countries analyzed in the European DNA vaccines market are:

•           Germany

•           The United Kingdom

•           France

•           Italy

•           Spain

•           Russia

•           Rest of Europe

The DNA vaccines market in Europe is mainly driven by the investments from the government, rising healthcare R&D expenditure and the prevalence of chronic & infectious diseases. Vaccines utilized in the present scenario in the European locale are made out of dead pathogens or live lessened infections, through DNA immunizations comprising of the DNA grouping of the antigen that is directed in individuals to invigorate an invulnerable reaction. In the European market, this strategy offers various customary procedures, including the incitement of both B-cell and T-cells portable reactions, ventured forward antibody dependability, the non-availability of any irresistible specialist and the relative simplicity of huge-scale testing. DNA vaccines are majorly used in the clinical research labs and diagnostic centers, mainly in countries such as the United Kingdom and Germany.

 Europe DNA vaccines market is expected to grow at a CAGR of 41.47% in terms of revenue for the forecasted years 2019-2027.

We provide additional customization based on your specific requirements. Request For Customization

The United Kingdom DNA vaccines market is developing at a rapid pace. The rising prevalence of chronic and infectious diseases, including cancer, HIV, high blood pressure, etc., are acting as a key driver for the growth of the DNA vaccines market in the country. According to the World Health Organization, 30.7% of the male and 25% of the female population is affected by high blood pressure in the United Kingdom. The prevalence of human immunodeficiency virus in the country accounted for 17.7% in 2015. These chronic and infectious diseases cause a large number of deaths every year. Hence, DNA vaccines are being adopted at a constant pace and are expected to treat chronic diseases in an effective and efficient manner in the country.

GlaxoSmithKline, Inc. is a research-based healthcare and pharmaceutical company that develops and discovers  medicines, vaccines,  as well as consumer healthcare products for customers in the United Kingdom and other countries, The company  provides medicines to treat a range of chronic and acute  diseases, such as HIV and respiratory disease, along with off-patent, local and generics products. In the year 2016, the company generated a revenue of about $35.95 billion. GlaxoSmithKline was founded in the year 1902 and has its headquarters in the Brentford, United Kingdom; it employs over 99,300 employees across the globe.

Related Reports

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027
Lifesciences

ASIA PACIFIC AESTHETIC LASER MARKET 2019-2027

Market By Type, Application, E ..

VIEW REPORT
ASIA PACIFIC BIOCHIPS MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOCHIPS MARKET 2019-2027

Market By Type, Substrate Mate ..

VIEW REPORT
ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027
Lifesciences

ASIA PACIFIC BIOPSY DEVICE MARKET 2019-2027

Market By Device Type, Therape ..

VIEW REPORT
ASIA PACIFIC DNA VACCINES MARKET 2019-2027
Lifesciences

ASIA PACIFIC DNA VACCINES MARKET 2019-2027

Market By Type, Application, T ..

VIEW REPORT
ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027
Lifesciences

ASIA-PACIFIC 3D CELL CULTURE MARKET 2019-2027

Market By Technology, Applicat ..

VIEW REPORT
ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028
Lifesciences

ASIA-PACIFIC AIRWAY CLEARANCE SYSTEM MARKET 2019-2028

Market By Application, Type, E ..

VIEW REPORT

Table of Content

1.    EUROPE DNA VACCINES MARKET - SUMMARY

2.    INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. PORTER’S FIVE FORCES OUTLOOK

2.2.1.   THREAT OF NEW ENTRANTS

2.2.2.   THREATS OF SUBSTITUTE PRODUCT

2.2.3.   BARGAINING POWER OF BUYER

2.2.4.   BARGAINING POWER OF SUPPLIER

2.2.5.   INTENSITY OF COMPETITIVE RIVALRY

2.3. VENDOR SCORECARD

2.4. VALUE CHAIN OUTLOOK

2.5. KEY INSIGHTS

2.6. REGULATORY FRAMEWORK

2.7. KEY BUYING OUTLOOK

2.8. MARKET DRIVERS

2.8.1.   SURGE IN NEW VACCINE DEVELOPMENT

2.8.2.   RISE IN THE USAGE OF DNA VACCINES FOR ANIMAL HEALTHCARE

2.8.3.   RISING PREVALENCE OF CHRONIC AND INFECTIOUS DISEASES

2.9. MARKET RESTRAINTS

2.9.1.   LACK OF LEGAL AND ETHICAL FRAMEWORK

2.9.2.   STRINGENT GOVERNMENT REGULATIONS

2.10.            MARKET OPPORTUNITIES

2.10.1.                GROWING DEMAND FOR GENE THERAPY

2.10.2.                STEADY VACCINES ARE EASY TO STORE AND TRANSPORT

2.10.3.                INCREASING NUMBER OF CLINICAL TRIALS ON HUMANS

2.11.            MARKET CHALLENGES

2.11.1.                VARIATION IN THE REGULATORY PATHWAY AND THE POINTS OF CONSIDERATION REGARDING ENVIRONMENTAL VALUATION

3.    DNA VACCINES MARKET OUTLOOK - BY TYPE

3.1. ANIMAL DNA VACCINE

3.2. HUMAN DNA VACCINE

4.    DNA VACCINES MARKET OUTLOOK - BY APPLICATION

4.1. HUMAN DISEASE

4.2. VETERINARY DISEASE

5.    DNA VACCINES MARKET OUTLOOK - BY TECHNOLOGY

5.1. PLASMID DNA VACCINES

5.2. PLASMID DNA DELIVERY

6.    DNA VACCINES MARKET OUTLOOK - BY REGION

6.1. EUROPE

6.1.1.   THE UNITED KINGDOM

6.1.2.   FRANCE

6.1.3.   GERMANY

6.1.4.   SPAIN

6.1.5.   ITALY

6.1.6.   RUSSIA

6.1.7.   REST OF EUROPE

7.    COMPETITIVE LANDSCAPE

7.1. ASTELLAS PHARMA, INC.

7.2. DENDREON CORPORATION (ACQUIRED BY SANPOWER GROUP)

7.3. ELI LILLY AND COMPANY

7.4. EUROGENTEC S.A.

7.5. GLAXOSMITHKLINE, INC.

7.6. INOVIO PHARMACEUTICALS, INC.

7.7. MADISON VACCINES, INCORPORATED (MVI)

7.8. MERCK & CO.

7.9. MERIAL LIMITED (ACQUIRED BY BOEHRINGER INGELHEIM)

7.10.            NOVARTIS AG

7.11.            SANOFI

7.12.            VGXI

7.13.            VICAL, INCORPORATED

7.14.            XENETIC BIOSCIENCES, INC.

7.15.            ZOETIS, INC.

8.    METHODOLOGY & SCOPE

8.1. RESEARCH SCOPE

8.2. SOURCES OF DATA

8.3. RESEARCH METHODOLOGY

List of table

TABLE 1        EUROPE DNA VACCINES MARKET 2019-2027 ($ MILLION)

TABLE 2        INTERVENTION AND PHASE OF SOME DISEASES/CONDITIONS

TABLE 3        REGULATIONS TO FOLLOW BEFORE COMMERCIALIZATION

TABLE 4        TEMPERATURE REQUIREMENT IN PRESERVATION FOR VARIOUS VACCINES

TABLE 5        APPROACHES BEING TESTED TO ENHANCE THE LOW IMMUNOGENICITY

TABLE 6        CLINICAL TRIALS ON HUMANS INVOLVING DNA VACCINES

TABLE 7        EUROPE DNA VACCINES MARKET BY TYPE 2019-2027 ($ MILLION)

TABLE 8        EUROPE DNA VACCINES MARKET BY APPLICATION 2019-2027 ($ MILLION)

TABLE 9        EUROPE DNA VACCINES MARKET BY TECHNOLOGY 2019-2027 ($ MILLION)

TABLE 10      EUROPE DNA VACCINES MARKET BY COUNTRY 2019-2027 ($ MILLION)

List of Figures

FIGURE 1      EUROPE DNA VACCINES MARKET 2019-2027 ($ MILLION)

FIGURE 2      VALUE CHAIN ANALYSIS FOR DNA VACCINE INDUSTRY

FIGURE 3      EUROPE DNA VACCINES MARKET IN VETERINARY DISEASES 2019-2027 ($ MILLION)

FIGURE 4      CLINICAL TRIALS OF GENE THERAPY

FIGURE 5      EUROPE DNA VACCINES MARKET IN ANIMAL DNA VACCINES 2019-2027 ($ MILLION)

FIGURE 6      EUROPE DNA VACCINES MARKET IN HUMAN DNA VACCINES 2019-2027 ($ MILLION)

FIGURE 7      EUROPE DNA VACCINES MARKET SHARE BY APPLICATION 2017 & 2026 (%)

FIGURE 8      EUROPE DNA VACCINES MARKET IN HUMAN DISEASES 2019-2027 ($ MILLION)

FIGURE 9      EUROPE DNA VACCINES MARKET IN VETERINARY DISEASES 2019-2027 ($ MILLION)

FIGURE 10   EUROPE DNA VACCINES MARKET IN PLASMID DNA VACCINES TECHNOLOGY 2019-2027 ($ MILLION)

FIGURE 11   EUROPE DNA VACCINES MARKET IN PLASMID DNA DELIVERY TECHNOLOGY 2019-2027 ($ MILLION)

FIGURE 12   THE UNITED KINGDOM DNA VACCINES MARKET 2019-2027 ($ MILLION)

FIGURE 13   FRANCE DNA VACCINES MARKET 2019-2027 ($ MILLION)

FIGURE 14   GERMANY DNA VACCINES MARKET 2019-2027 ($ MILLION)

FIGURE 15   SPAIN DNA VACCINES MARKET 2019-2027 ($ MILLION)

FIGURE 16   ITALY DNA VACCINES MARKET 2019-2027 ($ MILLION)

FIGURE 17   RUSSIA DNA VACCINES MARKET 2019-2027 ($ MILLION)

FIGURE 18   REST OF EUROPE DNA VACCINES MARKET 2019-2027 ($ MILLION)

Purchase Options

  • Licence Type
  • Price
  • User/Sharing
  • Printing
  • Delivery Formats
  • Free customization (Pre-sale)
  • Analyst hour support (Post Sale)
  • Customized notification for newly published report
  • Free report on update (within 180 days)

Single User PDF

$1,500.00

  • User/Sharing
  • Restricted to one authorized user
  • Printing
  • Not printable
  • Delivery Formats
  • Pdf
  • Free customization (Pre-sale)
  • 10% Free customization
  • Analyst hour support (Post Sale)
  • 3 hours
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Enterprise Online/PDF

$2,200.00

  • User/Sharing
  • Unlimited
  • Printing
  • Unlimited
  • Delivery Formats
  • Pdf and market estimation excel
  • Free customization (Pre-sale)
  • 20% Free customization
  • Analyst hour support (Post Sale)
  • 8 hour
  • Customized notification (newly published)
  • Free report on update (within 180 days)

Request free Sample

SUBMIT REQUEST
Request Custom Report

Request Custom Report

Enquire before buying

Enquire Before Buying

;